Related Experiment Video

Updated: Jul 12, 2026

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

Celiprolol, a compound possessing weak alpha 2-adrenergic antagonist properties in the dog

W S Mann, E F Sales, R G Van Inwegen

    Archives Internationales De Pharmacodynamie Et De Therapie
    |November 1, 1986
    PubMed

    More Related Videos

    Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine10:05

    Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

    Published on: July 7, 2016

    Electrocardiogram Recordings in Anesthetized Mice using Lead II04:16

    Electrocardiogram Recordings in Anesthetized Mice using Lead II

    Published on: June 20, 2020

    Related Concept Videos

    Adrenergic Agonists: Direct-Acting Agents01:30

    Adrenergic Agonists: Direct-Acting Agents

    Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
    These agents can be classified...
    Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

    Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

    Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
    Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
    Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

    Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

    β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
    Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

    Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

    β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
    Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

    Adrenergic Antagonists: ɑ and β-Receptor Blockers

    Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
    Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

    Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

    Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...